Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

Adrenal tumors arising from chromaffin cells will often accumulate radiolabeled metaiodobenzylguanidine (MIBG) and thus are amenable to therapy with I-131 MIBG. More recently, therapy studies have targeted the somatostatin receptors using Lu-177 or Y-90 radiolabeled somatostatin analogs. Because pheochromocytoma (PHEO)/paraganglioma (PGL) and neuroblastoma (NB), which often arise from the adrenals, express these receptors, clinical trials have been performed with these reagents. We will review the experience using radionuclide therapy for targeting PHEO/PGL and NBs. Copyright © 2012 Wiley Periodicals, Inc.


Jorge A Carrasquillo, Neeta Pandit-Taskar, Clara C Chen. Radionuclide therapy of adrenal tumors. Journal of surgical oncology. 2012 Oct 1;106(5):632-42

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 22718415

View Full Text